Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine.
Podrid P J, Kowey P R, Frishman W H, +4 more·The American journal of cardiology
Quinidine and procainamide have the potential for major organ toxicity, whereas mexiletine has been reported to have little risk of organ toxicity, serious proarrhythmia or congestive heart failure, but a relatively high incidence of nuisance side effects. In light of the potential adverse effects of all antiarrhythmic…